#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glomerulonephritis rapidly progressive Piriformis syndrome Toxic epidermal necrolysis Vascular malformation Haemophagocytic lymphohistiocytosis Glioblastoma multiforme Henoch-Schonlein purpura Leiomyosarcoma Gastrointestinal cancer metastatic Amyotrophic lateral sclerosis gene carrier Castleman's disease Thrombocytopenia Mucopolysaccharidosis III Necrotising myositis Extranodal marginal zone B-cell lymphoma (MALT type) More trials…

    Learn about Rare Diseases

    Cystic fibrosis lung – Treatment Antisynthetase syndrome – Diagnostics Advanced systemic mastocytosis – Trials in Disease Haemophilia A without inhibitors – Diagnostics Systemic mastocytosis – Treatment Mucous membrane pemphigoid – Basic Information Systemic sclerosis pulmonary – Life with Disease Alexander disease – Trials in Disease Rhabdoid tumour – Diagnostics Metachromatic leukodystrophy – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Quinidine Sulfate Linrodostat Mesilate Iomeprol Ly3298176 Idursulfase L-METHIONINE Salmeterol Xinafoate Navtemadlin Dinoprostone Sotatercept Mifamurtide Melphalan Hydrochloride IMMUNOSTEM APROTININ Baxdrostat Iohexol ANERATRIGINE MESILATE Afatinib Poloxamer 407 AGA2118 More therapies…

    Learn about Your Condition

    Relapsing multiple sclerosis Cachexia Hyperadrenocorticism Cancer pain Infectious pleural effusion Benign renal neoplasm Vertigo Hypoparathyroidism Mast cell activation syndrome Diabetic foot Hyperlipidaemia Essential hypertension Dementia Alzheimer's type Hepatic cirrhosis Heart disease congenital More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Praglandia s.r.o.

Praglandia s.r.o.

Nadrazni 3368/30a, Smichov, Prague, 150 00, Czechia

Want to learn more about this study or check if you can participate? Contact us.

  • Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Sonelokimab
    Bulgaria Croatia Czechia Estonia Finland France +10

  • Study on Long-term Safety and Effectiveness of Zasocitinib for Patients with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Zasocitinib
    Bulgaria Czechia France Germany Hungary Italy +3

  • Study on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Apremilast
    • Envudeucitinib
    Belgium Bulgaria Czechia Germany Poland Portugal

  • Study on Lu AG09222 for Preventing Migraines in Adults Unresponsive to Previous Treatments

    Not recruiting

    2 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Lu Ag09222
    Bulgaria Czechia Denmark France Germany Hungary +5

  • Study of amlitelimab injection compared to placebo for adults with severe alopecia areata (hair loss)

    Not recruiting

    2 1
    Investigated Diseases:
    • Alopecia areata
    Investigated Drugs:
    • Amlitelimab
    Bulgaria Czechia France Germany Italy The Netherlands +2

  • Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Nemolizumab
    Austria Belgium Bulgaria Czechia Estonia France +8

  • Study on the Safety and Effectiveness of Aticaprant with Antidepressants for Adults and Elderly with Major Depressive Disorder

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Major depression
    Investigated Drugs:
    • Aticaprant
    Belgium Bulgaria Czechia France Hungary Italy +5

  • Study on Aticaprant and Antidepressant for Preventing Relapse in Adults with Major Depressive Disorder and Anhedonia

    Not recruiting

    3 1
    Investigated Diseases:
    • Major depression
    Investigated Drugs:
    • Aticaprant
    Belgium Bulgaria Czechia France Germany Greece +3

  • Study on the Safety and Effectiveness of MEDI0618 for Reducing Migraine Days in Adults with Episodic Migraine

    Not recruiting

    2 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Medi0618
    Czechia Denmark Germany Hungary Italy The Netherlands +2

  • Study on the Effects of GSK1070806 Injection in Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Humanised Igg1 Kappa Monoclonal Antibody Against Interleukin 18
    Bulgaria Czechia France Germany Greece Italy +2
Previous Page
1 2 3 4 5 6
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!